DXCM Earnings & Financial Statements
DexCom, Inc.
$86.30
+$2.83(+3.39%)
51
Overall
55
Value
40
Tech
60
Quality
Market Cap
$31.50B
Volume
1.68M
52W Range
$54.11 - $92.59
Target Price
$96.04
DXCM earnings and financial statements: DexCom, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
DXCM Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $4.66B | $4.03B | $3.62B | $2.91B | $2.45B |
| Cost of revenue | $1.86B | $1.59B | $1.33B | $1.03B | $768.00M |
| Operating income | $911.80M | $600.00M | $597.70M | $391.20M | $265.80M |
| EBITDA | $1.36B | $945.70M | $916.70M | $565.30M | $377.60M |
| Net income | $836.30M | $576.20M | $541.50M | $341.20M | $216.90M |
| EPS (diluted) | $2.09 | $1.42 | $1.30 | $0.82 | $0.39 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $6.34B | $6.48B | $6.26B | $5.39B | $4.93B |
| Total liabilities | $3.59B | $4.38B | $4.20B | $3.26B | $2.89B |
| Shareholders’ equity | $2.75B | $2.10B | $2.07B | $2.13B | $2.04B |
| Cash and equivalents | $917.70M | $606.10M | $566.30M | $642.30M | $1.05B |
| Long-term debt | $1.31B | $1.30B | $2.51B | $1.29B | $2.08B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $1.44B | $989.50M | $748.50M | $669.50M | $442.50M |
| Capital expenditure | -$363.50M | -$358.80M | -$236.60M | -$364.80M | -$389.20M |
| Free cash flow | $1.08B | $630.70M | $511.90M | $304.70M | $53.30M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | DXCM | $86.30 | +3.4% | 1.68M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |